Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 Billion

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 Billion

UBS Downgrades Exact Sciences (EXAS) to Neutral

October 29, 2020 6:11 AM EDT

UBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).

The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More

Exact Sciences (EXAS) to Sell $869 Million of Common Stock in Registered Direct Offering

October 27, 2020 7:12 AM EDT

Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its common stock, par value $0.01 per share, in a registered direct offering to ten institutional investors, including some of its largest shareholders as well as healthcare specialist firms Casdin Capital and Rock Springs Capital.

Each Share is being sold for a purchase price of $101.00 per... More

Exact Sciences (EXAS) Q3 Revenues Beat

October 27, 2020 7:10 AM EDT

Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($1.46), which may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $408.4 million versus the consensus estimate of $337.37 million. COVID-19 testing revenue was $102.2 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

... More